These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32715655)

  • 21. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
    Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
    Lian L; Kim DD; Procyshyn RM; Cázares D; Honer WG; Barr AM
    PLoS One; 2022; 17(4):e0267808. PubMed ID: 35486616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral and Palmitate Paliperidone Long-Acting Injectable Formulations' Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP).
    Segarra R; Recio-Barbero M; Sáenz-Herrero M; Mentxaka O; Cabezas-Garduño J; Eguíluz JI; Callado LF
    Int J Neuropsychopharmacol; 2021 Sep; 24(9):694-702. PubMed ID: 34009370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
    Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R
    Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the Prophylaxis of Bipolar Disorder Type I with Manic Predominance.
    Mauri MC; Reggiori A; Minutillo A; Franco G; Pace CD; Paletta S; Cattaneo D
    Pharmacopsychiatry; 2020 Sep; 53(5):209-219. PubMed ID: 32155657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
    Jensen KG; Correll CU; Rudå D; Klauber DG; Decara MS; Fagerlund B; Jepsen JRM; Eriksson F; Fink-Jensen A; Pagsberg AK
    J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1062-1078. PubMed ID: 30858012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
    Citrome L
    Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial.
    Citrome L; Yagoda S; Bidollari I; Wang M
    J Clin Psychiatry; 2024 Feb; 85(1):. PubMed ID: 38416865
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison.
    Pae CU; Wang SM; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS; Serretti A; Emsley R
    Int Clin Psychopharmacol; 2017 Sep; 32(5):235-248. PubMed ID: 28430670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
    Fortea A; Ilzarbe D; Espinosa L; Solerdelcoll M; de Castro C; Oriolo G; Sugranyes G; Baeza I
    J Child Adolesc Psychopharmacol; 2018 May; 28(4):252-257. PubMed ID: 29381388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
    Vázquez-Bourgon J; Ibáñez Alario M; Mayoral-van Son J; Gómez Revuelta M; Ayesa Arriola R; Juncal Ruiz M; Ortiz-García de la Foz V; Crespo Facorro B
    Eur Neuropsychopharmacol; 2020 Oct; 39():46-55. PubMed ID: 32891516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
    Patel R; Chesney E; Taylor M; Taylor D; McGuire P
    Psychol Med; 2018 Jul; 48(10):1616-1623. PubMed ID: 29039277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone is not only a prodrug: psychosis induced by medication switch from risperidone to paliperidone - a case report.
    Dagenais-Beaulé V
    Eur J Hosp Pharm; 2023 Jul; 30(4):e20. PubMed ID: 34785566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed.
    Meyer JM
    CNS Spectr; 2017 Dec; 22(S1):14-28. PubMed ID: 29350127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia.
    Kishi T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jan; 132():144-150. PubMed ID: 33096355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
    Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
    Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics.
    Bonete Llácer JM; Martínez Hortelano A; Richart Albelda B
    Int J Psychiatry Clin Pract; 2019 Sep; 23(3):189-193. PubMed ID: 30848967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.